3Kraseman n C,Meyer JM,Springsklee M.Moxifloxacin (MFX)in community-acquired pneumonia(CAP)- A bacteriologic and clinical meta analysis[].Clin M- icrobiol Infect.1999
二级参考文献11
1Aktas Z,GonulluN,SalciogluM,et a1.Moxifloxacin activity against clinical isolates compared with the activity Of ciprofloxacin.Int-J-Antimicrob-Agents,2002,20:196.
2Krasemann C,MeyerJ,Tillotson G Evaluation Of the clinical microbiology profile of moxifioxacin.Clin Infect Dis,2001,32 Suppl l:S51-63.
3Davidson RJ,Fuller J,Low DE.Pharmacodynamic properties of moxifloxacin,levofloxacin, and clarithromycin in S.pneumoniae and H.infiuenzae [abstract] 36th ICAAC;Sep 24;SanDiego:227.
4JacobsE,DalhoffA,BrunnerU.Efficacy Of BAYl2-8039 in Mycoplasma pneumoniae infected guinea pigs .36th Interscience Conference On Antimicrobial Agents and Chemotherapy;1997 Sep 15-18:New Orleans,Louisiana:102.
5Visalli MA,Jacobs MR,Appelbaum PC.Antipneumococcal activity Of BAYl3-8039,a new quinolone, compared with activities Of three other quinolones and four oral beta-lactams.Antimicrob Agents Chemother,1997,41:1786.
6National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing:eleventh informational supplement .NCCLS documents.2002,78.
7Coudron PE, Moland ES, Thomson KS. Occurrence and Detection Of AmpC Beta-Lactamase amone Escherichia coli,Klebsiella pneumoniae , and Proteus mirabilis isolates at a Veterans Medical Center.J. Clin Microb.2000,38(5),1791.
8Sahm DF, Washington II JA.Antibacterial susceptibility tests:dilution methods.Manual of clinical microbiology, 6th ed.1995:1117.
9National Committee for Clinical Laboratory Standards. Performance Standard for antimicrobial susceptibility testing: eleventh informational supplement .NCCLS documents.2001,93.
10Jacobs MR,Appelbaum PC,Felmingham D.The Alexander project group. Penicillin resistance in S.pneumoniae.Clin Microbiol lnf.2000,6 Supple l:28.
